BTIG Maintains Buy on Tvardi Therapeutics, Lowers Price Target to $15
Benzinga Newsdesk 1 year ago
NewsPrice TargetAnalyst Ratings
BTIG analyst Julian Harrison maintains Tvardi Therapeutics (NASDAQ:TVRD) with a Buy and lowers the price target from $55 to $15.
BTIG analyst Julian Harrison maintains Tvardi Therapeutics (NASDAQ:TVRD) with a Buy and lowers the price target from $55 to $15.